On July 5, I logged into my trading account at LowTrades to check on the per share price of a single stock - Hemispherx Biopharma (AMEX:HEB). On the Google Finance discussion boards, everyone is abuzz with excitement as stock quoting platforms across the internet return quotes of $29.84 per share for Hemispherx, up from Thursday evening's close of $2.54 per share.

Yep. There it was! Hemispherix Biopharma had somehow grown during non-trading hours from $2.54 per share to $29.84 per shar... Read More

0 comments View Entry

The FDA has fallen weeks behind schedule in responding to select NDA's and PDUFA's. While people across the globe continue to fall ill, suffer and die from disease and debilitations, American drug research and development companies such as Cell Therapeutics (NASDAQ:CTIC), Hemispherx Biopharma (AMEX:HEB), BioDelivery Sciences International (NASDAQ:BDSI), Discovery Laboratories (NASDAQ:DSCO), Acura Phamaceuticals (NASDAQ:ACUR), King Pharmaceuticals (NYSE:KG) and Genta (OTC:GNTA) sit by anxiousl... Read More

0 comments View Entry

Following the close of market, biotech stock investors were excited and filled with a new breath of reassurance for their investment holdings in Cell Therapuetics (NASDAQ:CTIC) and Hemispherx Biopharma (AMEX:HEB) today. Given a sharp boost by their inclusion today in the Russell 3000, Cell Therapeutics closed at $1.85 (+0.28 +17.83%) while Hemispherx took the stage at $2.85 (+0.45 +18.75%).

The real buzz and excitement followed after hours for Hemispherx investors. Reports of after hou... Read More

0 comments View Entry